TMBR

Timber Pharmaceuticals, Inc.

TMBR

Market cap $1.18M

Delisted

TMBR was delisted on the 28th of November, 2023.

Back to rankings

About: Timber Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. Its investigational therapies have mechanisms of action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing, and control) and safety profiles. The company is focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), X-linked recessive CI (XLRI) and autosomal recessive CI (ARCI), and other sclerotic skin diseases. The company's late-stage program is TMB-001., and TMB-003 is the earliest-stage program.

Employees: 9

Healthcare Drug Manufacturers - General

Financial journalist opinion

MSG Networks in talks to avoid bankruptcy — possibly with help of Amazon: sources

MSG Networks, the embattled cable TV station that airs New York Knicks and Rangers games, is in talks to reach a deal to avoid bankruptcy as soon as Friday.

MSG Networks in talks to avoid bankruptcy — possibly with help of Amazon: sources

Timber Pharmaceuticals, Inc., a LEO Pharma Company, Provides an Update on the Development Program for TMB-001 in Congenital Ichthyosis

MADISON, N.J.--(BUSINESS WIRE)--NOT FOR UK USE – NOT INTENDED FOR UK MEDIA Timber Pharmaceuticals Inc., a LEO Pharma company, today announced the results for the randomized, double-blind 12-week period of the ASCEND trial. The trial did not show a statistically significant difference between the proportion of patients treated with TMB-001 responding to treatment after 12 weeks compared with patients treated with vehicle. ASCEND is the phase 3 clinical trial of TMB-001, an investigational topica.

Timber Pharmaceuticals, Inc., a LEO Pharma Company, Provides an Update on the Development Program for TMB-001 in Congenital Ichthyosis

Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting

MADISON, N.J.--(BUSINESS WIRE)--Timber Pharmaceuticals, Inc., a LEO Pharma Comp., Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis CI.

Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting

LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma today announced that it has finalized the acquisition of the strategic asset TMB-001 as well as certain other assets from Timber Pharmaceuticals following its chapter 11 bankruptcy filing. The TMB-001 project aims to develop a topical treatment for multiple moderate to severe subtypes of congenital ichthyosis – a skin disease with significant unmet need and no approved prescription therapies available. The TMB-001 project continues as planned and w.

LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals

Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

WARREN, N.J., Nov. 29, 2023 — Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the staff of NYSE Regulation (the “NYSE Regulation”) has determined to immediately suspend trading in the Company's common stock from NYSE American, LLC (the “NYSE American”).

Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market

NYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to immediately suspend trading in the common stock of Timber Pharmaceuticals, Inc. (the “Company”) — ticker symbol TMBR — from NYSE American. On November 21, 2023, the NYSE American announced that it was commencing proceedings to delist the Company. The Company had the right to request a review of this determination by the Listings Qualifications Pane.

NYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)

Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American

WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-in-possession ("Timber" or the "Company"), today announced that all "first day" motions related to the Company's voluntary Chapter 11 petitions for reorganization filed on November 17, 2023, were approved on an interim basis by the U.S. Bankruptcy Court for the District of Delaware.

Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American

NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals, Inc. (TMBR)

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Timber Pharmaceuticals, Inc. (the “Company”) — ticker symbol TMBR — from NYSE American. NYSE Regulation has determined that the Company is no longer suitable for listing and will commence delisting proceedings pursuant to Section 1003(c)(iii) of the NYSE American Company Guide in light of the Compa.

NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals, Inc. (TMBR)

See News Rankings

Charts implemented using Lightweight Charts™